Skip to main content

Navigation group

Type at least 3 characters
1,330 articles

Articles

Original Research

Published on 04 Sep 2024

A phase III study to access the safety and efficacy of prolgolimab 250 mg fixed dose administered every 3 weeks versus prolgolimab 1 mg/kg every 2 weeks in patients with metastatic melanoma (FLAT)

in Cancer Immunity and Immunotherapy

  • Lev Demidov
  • Galina Kharkevich
  • Natalia Petenko
  • Vladimir Moiseenko
  • Svetlana Protsenko
  • Tatiana Semiglazova
  • Anastasia Zimina
  • Nadezhda Kovalenko
  • Natalia Fadeeva
  • Dmitry Kirtbaya
A phase III study to access the safety and efficacy of prolgolimab 250 mg fixed dose administered every 3 weeks versus prolgolimab 1 mg/kg every 2 weeks in patients with metastatic melanoma (FLAT)
Frontiers in Oncology
doi 10.3389/fonc.2024.1385685
  • 1,012 views